Immunological mutational signature in adenosquamous cancer of pancreas: an exploratory study of potentially therapeutic targets

Nicola Silvestris, Oronzo Brunetti, Rosamaria Pinto, Daniela Petriella, Antonella Argentiero, Livia Fucci, Stefania Tommasi, Katia Danza, Simona De Summa

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objectives: Adenosquamous cancer of pancreas (ASCP) is a rare variant of pancreatic adenocarcinoma (PDAC). It is characterized by poor prognosis and lacks of literature data supporting the choice of systemic therapies. The role of immunotherapy for this malignancy is still unknown. In this study, we evaluated any differences between immune-related genes of PDAC and its adenosquamous variant with the aim to characterize these histothistotypes and eventually identify potential biomarkers useful for an immune-therapy approach in ASCP. Methods: We compared the mutational status of a customized gene panel, including 41 genes involved in immunity checkpoint, inflammation and control of leukocytes, B and T cells proliferation of PDAC and ASCP. Moreover, we evaluated the immunohistochemical expression of programmed death ligand 1 (PD-L1). Results: We observed a status of ‘hypermutation’ of genes included in our panel in ASCP (22/41 mutated genes). Furtheremore, PD-L1 was found to be expressed in about 15% of the squamous component of ASCP tissue. Conclusion: Due to genetic characteristics and to PD-L1 expression in ASCP compared to PDAC tissue, we can conclude that ASCP presents a potential sensitivity to immunological therapy.

Original languageEnglish
Pages (from-to)453-461
Number of pages9
JournalExpert Opinion on Therapeutic Targets
Volume22
Issue number5
DOIs
Publication statusPublished - May 4 2018

Fingerprint

Pancreatic Neoplasms
Genes
Ligands
Tissue
Therapeutics
T-cells
Cell proliferation
Biomarkers
Immunotherapy
Immunity
Adenocarcinoma
Leukocytes
B-Lymphocytes
Cell Proliferation
Inflammation
T-Lymphocytes
Neoplasms

Keywords

  • Adenosquamous carcinoma of pancreas
  • Immunological mutational signature
  • Immunological therapeutic targets
  • Pancreatic ductal adenocarcinoma

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

Immunological mutational signature in adenosquamous cancer of pancreas : an exploratory study of potentially therapeutic targets. / Silvestris, Nicola; Brunetti, Oronzo; Pinto, Rosamaria; Petriella, Daniela; Argentiero, Antonella; Fucci, Livia; Tommasi, Stefania; Danza, Katia; De Summa, Simona.

In: Expert Opinion on Therapeutic Targets, Vol. 22, No. 5, 04.05.2018, p. 453-461.

Research output: Contribution to journalArticle

Silvestris, Nicola ; Brunetti, Oronzo ; Pinto, Rosamaria ; Petriella, Daniela ; Argentiero, Antonella ; Fucci, Livia ; Tommasi, Stefania ; Danza, Katia ; De Summa, Simona. / Immunological mutational signature in adenosquamous cancer of pancreas : an exploratory study of potentially therapeutic targets. In: Expert Opinion on Therapeutic Targets. 2018 ; Vol. 22, No. 5. pp. 453-461.
@article{dab3cb97b64844a0ae248c03003bf206,
title = "Immunological mutational signature in adenosquamous cancer of pancreas: an exploratory study of potentially therapeutic targets",
abstract = "Objectives: Adenosquamous cancer of pancreas (ASCP) is a rare variant of pancreatic adenocarcinoma (PDAC). It is characterized by poor prognosis and lacks of literature data supporting the choice of systemic therapies. The role of immunotherapy for this malignancy is still unknown. In this study, we evaluated any differences between immune-related genes of PDAC and its adenosquamous variant with the aim to characterize these histothistotypes and eventually identify potential biomarkers useful for an immune-therapy approach in ASCP. Methods: We compared the mutational status of a customized gene panel, including 41 genes involved in immunity checkpoint, inflammation and control of leukocytes, B and T cells proliferation of PDAC and ASCP. Moreover, we evaluated the immunohistochemical expression of programmed death ligand 1 (PD-L1). Results: We observed a status of ‘hypermutation’ of genes included in our panel in ASCP (22/41 mutated genes). Furtheremore, PD-L1 was found to be expressed in about 15{\%} of the squamous component of ASCP tissue. Conclusion: Due to genetic characteristics and to PD-L1 expression in ASCP compared to PDAC tissue, we can conclude that ASCP presents a potential sensitivity to immunological therapy.",
keywords = "Adenosquamous carcinoma of pancreas, Immunological mutational signature, Immunological therapeutic targets, Pancreatic ductal adenocarcinoma",
author = "Nicola Silvestris and Oronzo Brunetti and Rosamaria Pinto and Daniela Petriella and Antonella Argentiero and Livia Fucci and Stefania Tommasi and Katia Danza and {De Summa}, Simona",
year = "2018",
month = "5",
day = "4",
doi = "10.1080/14728222.2018.1456530",
language = "English",
volume = "22",
pages = "453--461",
journal = "Expert Opinion on Therapeutic Targets",
issn = "1472-8222",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Immunological mutational signature in adenosquamous cancer of pancreas

T2 - an exploratory study of potentially therapeutic targets

AU - Silvestris, Nicola

AU - Brunetti, Oronzo

AU - Pinto, Rosamaria

AU - Petriella, Daniela

AU - Argentiero, Antonella

AU - Fucci, Livia

AU - Tommasi, Stefania

AU - Danza, Katia

AU - De Summa, Simona

PY - 2018/5/4

Y1 - 2018/5/4

N2 - Objectives: Adenosquamous cancer of pancreas (ASCP) is a rare variant of pancreatic adenocarcinoma (PDAC). It is characterized by poor prognosis and lacks of literature data supporting the choice of systemic therapies. The role of immunotherapy for this malignancy is still unknown. In this study, we evaluated any differences between immune-related genes of PDAC and its adenosquamous variant with the aim to characterize these histothistotypes and eventually identify potential biomarkers useful for an immune-therapy approach in ASCP. Methods: We compared the mutational status of a customized gene panel, including 41 genes involved in immunity checkpoint, inflammation and control of leukocytes, B and T cells proliferation of PDAC and ASCP. Moreover, we evaluated the immunohistochemical expression of programmed death ligand 1 (PD-L1). Results: We observed a status of ‘hypermutation’ of genes included in our panel in ASCP (22/41 mutated genes). Furtheremore, PD-L1 was found to be expressed in about 15% of the squamous component of ASCP tissue. Conclusion: Due to genetic characteristics and to PD-L1 expression in ASCP compared to PDAC tissue, we can conclude that ASCP presents a potential sensitivity to immunological therapy.

AB - Objectives: Adenosquamous cancer of pancreas (ASCP) is a rare variant of pancreatic adenocarcinoma (PDAC). It is characterized by poor prognosis and lacks of literature data supporting the choice of systemic therapies. The role of immunotherapy for this malignancy is still unknown. In this study, we evaluated any differences between immune-related genes of PDAC and its adenosquamous variant with the aim to characterize these histothistotypes and eventually identify potential biomarkers useful for an immune-therapy approach in ASCP. Methods: We compared the mutational status of a customized gene panel, including 41 genes involved in immunity checkpoint, inflammation and control of leukocytes, B and T cells proliferation of PDAC and ASCP. Moreover, we evaluated the immunohistochemical expression of programmed death ligand 1 (PD-L1). Results: We observed a status of ‘hypermutation’ of genes included in our panel in ASCP (22/41 mutated genes). Furtheremore, PD-L1 was found to be expressed in about 15% of the squamous component of ASCP tissue. Conclusion: Due to genetic characteristics and to PD-L1 expression in ASCP compared to PDAC tissue, we can conclude that ASCP presents a potential sensitivity to immunological therapy.

KW - Adenosquamous carcinoma of pancreas

KW - Immunological mutational signature

KW - Immunological therapeutic targets

KW - Pancreatic ductal adenocarcinoma

UR - http://www.scopus.com/inward/record.url?scp=85044477894&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044477894&partnerID=8YFLogxK

U2 - 10.1080/14728222.2018.1456530

DO - 10.1080/14728222.2018.1456530

M3 - Article

C2 - 29561217

AN - SCOPUS:85044477894

VL - 22

SP - 453

EP - 461

JO - Expert Opinion on Therapeutic Targets

JF - Expert Opinion on Therapeutic Targets

SN - 1472-8222

IS - 5

ER -